130 related articles for article (PubMed ID: 38071748)
1. Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.
Albuquerque J; Neto da Silva D; Padrão T; Leal-Costa L; Bizarro R; Correia J; Baptista C; Machete M; Prazeres G; Margarido I; Fernandes G; Simões P; Timóteo T; Lopes F; Godinho J; Moreira-Pinto J; Rodrigues T; Faria A; Pulido C; Cirnes L; Teixeira JA; Passos Coelho JL
Oncologist; 2024 Mar; 29(3):e337-e344. PubMed ID: 38071748
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced Reversion of Mutant
Sato S; Mikayama YO; Shiozawa M; Nukada S; Iguchi K; Okamoto H; Kohmura T; Kazama K; Tanaka K; Oshima T; Rino Y
Anticancer Res; 2022 May; 42(5):2625-2635. PubMed ID: 35489751
[TBL] [Abstract][Full Text] [Related]
3. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature.
Osumi H; Vecchione L; Keilholz U; Vollbrecht C; Alig AHS; von Einem JC; Stahler A; Striefler JK; Kurreck A; Kind A; Modest DP; Stintzing S; Jelas I
Eur J Cancer; 2021 Aug; 153():86-95. PubMed ID: 34153718
[TBL] [Abstract][Full Text] [Related]
4. Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol.
Osumi H; Ishizuka N; Takashima A; Kumekawa Y; Nakano D; Shiozawa M; Denda T; Sawada R; Ouchi K; Wakatsuki T; Narikazu B; Kato K; Yamaguchi K; Shinozaki E
BMJ Open; 2022 Sep; 12(9):e063071. PubMed ID: 36581973
[TBL] [Abstract][Full Text] [Related]
5. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Napolitano S; De Falco V; Martini G; Ciardiello D; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Bordonaro R; Scartozzi M; Santini D; Di Maio M; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T
JAMA Oncol; 2023 Jul; 9(7):966-970. PubMed ID: 37200022
[TBL] [Abstract][Full Text] [Related]
6. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis.
Chen J; Ye Y; Sun H; Shi G
Cancer Chemother Pharmacol; 2013 Jan; 71(1):265-72. PubMed ID: 23090619
[TBL] [Abstract][Full Text] [Related]
7. Receipt of Targeted Therapy and Survival Outcomes in Patients With Metastatic Colorectal Cancer.
Koroukian SM; Booker BD; Vu L; Schumacher FR; Rose J; Cooper GS; Selfridge JE; Markt SC
JAMA Netw Open; 2023 Jan; 6(1):e2250030. PubMed ID: 36656585
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
[TBL] [Abstract][Full Text] [Related]
9. Anti-epidermal growth factor receptor treatment for patients with Neo
Harada K; Yuki S; Kawamoto Y; Nakamura T; Kaneko S; Ishida K; Sakamoto N; Komatsu Y
Ther Adv Med Oncol; 2023; 15():17588359231216090. PubMed ID: 38033418
[TBL] [Abstract][Full Text] [Related]
10. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
Osumi H; Takashima A; Ooki A; Yoshinari Y; Wakatsuki T; Hirano H; Nakayama I; Okita N; Sawada R; Ouchi K; Fukuda K; Fukuoka S; Ogura M; Takahari D; Chin K; Shoji H; Kato K; Ishizuka N; Boku N; Yamaguchi K; Shinozaki E
Transl Oncol; 2023 Sep; 35():101718. PubMed ID: 37364334
[TBL] [Abstract][Full Text] [Related]
11. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
12. Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic.
Ghatalia P; Smith CH; Winer A; Gou J; Kiedrowski LA; Slifker M; Saltzberg PD; Bubes N; Anari FM; Kasireddy V; Varshavsky A; Liu Y; Ross EA; El-Deiry WS
Front Oncol; 2018; 8():652. PubMed ID: 30705875
[No Abstract] [Full Text] [Related]
13. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study.
Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y
EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945
[TBL] [Abstract][Full Text] [Related]
14. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
Chen SH; Tsai HL; Jiang JK; Sung YC; Huang CW; Yeh YM; Chen LT; Wang JY
BMC Cancer; 2019 Jun; 19(1):640. PubMed ID: 31253124
[TBL] [Abstract][Full Text] [Related]
15. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsies in Progressing Metastatic Colorectal Cancer- Application and their Therapeutic Implications According to the RAS Status.
Pereira J; Alves F; Ferreira F; Vasconcelos de Matos L; Massena A; Martins A
Cureus; 2020 Feb; 12(2):e7035. PubMed ID: 32211268
[TBL] [Abstract][Full Text] [Related]
18. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
Normanno N; Esposito Abate R; Lambiase M; Forgione L; Cardone C; Iannaccone A; Sacco A; Rachiglio AM; Martinelli E; Rizzi D; Pisconti S; Biglietto M; Bordonaro R; Troiani T; Latiano TP; Giuliani F; Leo S; Rinaldi A; Maiello E; Ciardiello F;
Ann Oncol; 2018 Jan; 29(1):112-118. PubMed ID: 28950295
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
[TBL] [Abstract][Full Text] [Related]
20. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]